Morepen Laboratories (NSE:MOREPENLAB) Other Stockholders Equity: ₹11,369 Mil (As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
75 GF Score
Price ₹59.12
GF Value ₹50.02
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Morepen Laboratories Other Stockholders Equity?

Morepen Laboratories NSE:MOREPENLAB +8.16% 75 Other Stockholders Equity is ₹11,369 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹50.02 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Morepen Laboratories's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹11,369 Mil.

Morepen Laboratories's quarterly Other Stockholders Equity declined from Sep. 2025 (₹10,866 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹11,369 Mil).

Morepen Laboratories's annual Other Stockholders Equity increased from Mar. 2024 (₹128 Mil) to Mar. 2025 (₹131 Mil) and increased from Mar. 2025 (₹131 Mil) to Mar. 2026 (₹11,369 Mil).

Morepen Laboratories Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Other Stockholders Equity Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 236.27 146.47 128.05 130.59 11,368.55

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.59 0.00 10,866.50 0.00 11,368.55
NSE:MOREPENLAB
75GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹11,369 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Other Stockholders Equity of ₹11,369 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Other Stockholders Equity too high?
Morepen Laboratories' current Other Stockholders Equity is ₹11,369 Mil. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Other Stockholders Equity compare to ZTS and UTHR?
Morepen Laboratories' Other Stockholders Equity of ₹11,369 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Other Stockholders Equity is ₹11,369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹50.02, compared to a current price of ₹59.12 — trading 18.2% above its estimated fair value. The current Other Stockholders Equity is ₹11,369 Mil. Morepen Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Other Stockholders Equity is ₹11,369 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹59.12 is trading 18.2% above its estimated GF Value™ of ₹50.02. GuruFocus considers Morepen Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Other Stockholders Equity: ₹11,369 Mil
  • GF Value™: ₹50.02 vs. price of ₹59.12 (18.2% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score

Get the complete analysis for NSE:MOREPENLAB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹59.12
Price
₹50.02
GF Value